An Improved Score for the Evaluation of Mucosal Healing in Inflammatory Bowel Disease—A Pilot Study

Inflammatory bowel diseases are chronic conditions characterized by periods of remission, alternating with episodes of exacerbation, in which the primary therapeutic target is mucosal healing. Although colonoscopy is currently considered the gold standard for assessing disease activity, it presents a significant number of disadvantages. Over time, various inflammatory biomarkers have been proposed to detect disease activation, but current biomarkers have many limitations. Our study aimed to analyze the most commonly used biomarkers for patient monitoring and follow-up both independently and taken together as a group, in order to propose an improved activity score that more accurately reflects the changes occurring at the intestinal level, in order to limit the number of colonoscopic interventions. By applying logistic regression as a method of statistical analysis to the retrospectively collected data, we obtained an easy-to-calculate improved score that quantifies the chance that a given patient may be in remission or in a period of endoscopic activity. To achieve a widely accessible score that is easily accessible in clinical practice, we have included only the most commonly used clinical and biological parameters.

[1]  C. Matei,et al.  Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission , 2020, Medicina.

[2]  Mariusz A. Bromke,et al.  Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults , 2020, Diagnostics.

[3]  B. Click,et al.  The burden of cost in inflammatory bowel disease: a medical economic perspective. , 2020, Current opinion in gastroenterology.

[4]  S. Vermeire,et al.  The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. , 2020, Journal of Crohn's & colitis.

[5]  J. Feuerstein,et al.  Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments , 2019, World journal of gastroenterology.

[6]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. , 2018, Journal of Crohn's & colitis.

[7]  Shan Gao,et al.  Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China , 2017, World journal of gastroenterology.

[8]  Jana G Hashash,et al.  A comprehensive review and update on Crohn's disease. , 2017, Disease-a-month : DM.

[9]  M. Barreiro-de Acosta,et al.  Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study , 2016, Journal of clinical gastroenterology.

[10]  E. de Boer,et al.  High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score , 2016, Digestive Diseases and Sciences.

[11]  Steven J Brown,et al.  Cost-effectiveness of Crohn's disease post-operative care. , 2016, World journal of gastroenterology.

[12]  T. Voiosu,et al.  Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[13]  M. Färkkilä,et al.  Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2013, Scandinavian journal of gastroenterology.

[14]  M. Färkkilä,et al.  Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2012, Scandinavian journal of gastroenterology.

[15]  J. Jahnsen,et al.  Fecal calprotectin variability in Crohn's disease. , 2010, Inflammatory bowel diseases.

[16]  A. Schoepfer,et al.  Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI , 2010, The American Journal of Gastroenterology.

[17]  J. Ellenberg,et al.  Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis , 2008, Inflammatory bowel diseases.

[18]  A. Michalsen,et al.  Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.

[19]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[20]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  S. Fais,et al.  The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. , 1988, Journal of clinical gastroenterology.